Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer.
Fiche publication
Date publication
juillet 2021
Journal
European journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno
Tous les auteurs :
Petitcollin A, Azzopardi N, Pierga JY, Ternant D, Navarro-Teulon I, Desvignes C, Mouret-Reynier MA, Coudert B, Paintaud G
Lien Pubmed
Résumé
To describe the sources of interindividual variability of bevacizumab and trastuzumab pharmacokinetics in early-stage breast cancer, and to study the relationship between exposure and both early clinical response and specific adverse events.
Mots clés
Bevacizumab, Breast cancer, Monoclonal antibodies, Population pharmacokinetics, Trastuzumab
Référence
Eur J Clin Pharmacol. 2021 Jul 10;: